TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06014528: A Multicenter, Randomized, Double-Blind, Phase II Clinical Study of IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent

Sponsor: InxMed (Shanghai) Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 168 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06014528 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06014528 Rescue Dossier →